- Privately-held Bellicum Pharmaceuticals pays Ariad Pharmaceuticals (NASDAQ:ARIA) $50M for a full license to Ariad's cell-signalling technology. Under the terms of the revised agreement, Ariad will receive $15M upon the signing of the agreement, $20M by June 30, 2015 and $15M by June 30, 2016. Bellicum's license will be free of milestone and royalty payments.
- Bellicum is developing controllable stem cell transplant, chimeric antigen receptor T cell and cancer vaccine product candidates for a variety of diseases.